# TB-500: Research Overview — Avenger Peptides > A plain-language literature summary of TB-500 (Ac-LKKTETQ), a synthetic fragment of thymosin beta-4 studied for tissue repair. The fragment-versus-full-protein distinction, actin biology, and safety signals explained. The Ac-LKKTETQ heptapeptide holds thymosin beta-4's actin-binding motif — but most of the healing evidence in the literature comes from the full parent protein, not the fragment itself. ## The short version TB-500 is a small synthetic peptide of just seven amino acids: Ac-LKKTETQ. That sequence is the *actin-binding* piece of a larger natural protein called thymosin beta-4 (Tβ4). Actin is part of the internal skeleton cells use to hold their shape and to crawl toward a wound, so the parent protein is closely tied to cell movement, healing, and new blood-vessel growth [8]. The single most important fact about TB-500 is a naming gap. In commerce and in anti-doping labs, "TB-500" means the short seven-amino-acid fragment. But most published *effectiveness* research was done with the full-length protein, which is roughly five times heavier [8]. Whether the small fragment reproduces what the whole protein does has not been established in controlled human trials [6]. TB-500 is not an approved medicine, it is banned in sport, and this page reports any doses only as they were studied in animals — never as advice. ## What it is TB-500 is a synthetic, N-terminally acetylated heptapeptide — seven amino acids with a small chemical cap (acetyl group) on one end — with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. This `LKKTETQ` stretch maps to residues 17–23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein, and it is the conserved *actin-binding* region shared across the beta-thymosin family. The size distinction matters throughout: the fragment sold as "TB-500" weighs about 889 daltons, while full-length Tβ4 is about 4,963 daltons. Wherever a study below used the full protein rather than the 7-mer, this page flags it — that is exactly where TB-500 marketing most often borrows a larger molecule's data [8]. ## How it works Full-length thymosin beta-4 is the body's major intracellular *G-actin sequestering* peptide. G-actin is the free, single-unit form of actin; sequestering means Tβ4 grabs and holds those units in reserve so they are not assembled into filaments until the cell needs them. X-ray crystallography established that Tβ4 forms a 1:1 complex with G-actin and caps both ends of the monomer, preventing it from polymerizing — the structural basis for its actin-buffering role [10]. Why does actin buffering matter for repair? By regulating the actin skeleton, Tβ4 (and the LKKTETQ motif it carries) is linked to faster cell migration, new blood-vessel growth, reduced scar-forming myofibroblasts, anti-inflammatory signaling, and recruitment of progenitor cells [8]. Think of it as controlling the cell's internal scaffolding so it can pack up and move toward a wound. Whether the isolated seven-amino-acid fragment reliably does all of this at the doses used in peptide research has not been confirmed in controlled human trials [8]. ## What the research shows *Structural and mechanistic basis.* X-ray crystallography of a gelsolin-Tβ4 hybrid bound to actin (at 2-angstrom resolution) established the 1:1 G-actin sequestration mechanism via dual-end capping [10]. A 2012 multi-model review consolidated the actin-binding, pro-migratory, anti-scarring, anti-inflammatory, and angiogenic activities of Tβ4 as the basis for clinical development in dermal wounds, corneal injury, heart, and CNS repair [8]. *A cardiac repair signal in mice.* In mouse cardiomyocytes and after coronary artery ligation, Tβ4 formed a complex with the proteins PINCH and ILK, activating the survival kinase Akt, enhancing early myocyte survival, and improving cardiac function post-ligation [11]. *Wound healing in rats.* Topical or intraperitoneal thymosin beta-4 in a rat full-thickness wound model increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, with increased wound contraction and raised collagen and angiogenesis; as little as 10 picograms stimulated keratinocyte migration 2–3-fold [12]. (Full-length Tβ4, not the 7-mer.) *Human safety — full-length protein only.* In a randomized, placebo-controlled Phase 1 study, intravenous thymosin beta-4 was given to 40 healthy volunteers at 42, 140, 420, or 1260 mg — a single dose then daily for 14 days. It was well tolerated: infrequent mild-to-moderate adverse events, no dose-limiting toxicities, no serious adverse events, and dose-proportional pharmacokinetics [9]. This used full-length Tβ4, not the TB-500 fragment. *Non-monotonic dose-response.* In rats with an embolic stroke, intraperitoneal Tβ4 at 2 and 12 mg/kg improved neurological function from day 14 through day 56, but 18 mg/kg gave no significant benefit [7]. More is not necessarily better. *Field review.* A 2026 Sports Medicine narrative review of unapproved peptides for musculoskeletal injury and athletic performance concluded that many show favorable animal-model outcomes but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight [6]. ## Reported effects, cautions and safety The cautions for TB-500 are specific and several of them are unique to this compound: - *Identity confusion is the core problem.* "TB-500" on a label means the 7-mer fragment, but most efficacy data come from full-length Tβ4 — about five times larger. Efficacy claims for the fragment in humans are unproven [8]. No completed controlled clinical trials of the TB-500 fragment exist for any indication [6]. - *Tumor and angiogenesis signal.* Thymosin beta-4 is overexpressed in several cancers (pancreatic, colorectal) and is implicated in metastasis and tumor blood-vessel growth. The same pro-migratory, pro-angiogenic properties that aid wound repair could theoretically support tumor progression [8]. - *Mixed and negative preclinical results.* In muscular-dystrophy mice, chronic Tβ4 increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis. Systemic Tβ4 also failed to reduce myocardial ischemia-reperfusion injury in a pig study [6]. - *Non-monotonic dosing.* The rat stroke study found that 18 mg/kg was no better than no treatment, while 12 mg/kg helped — higher dosing is not guaranteed to be better, which undermines community loading rationales [7]. - *Regulatory.* TB-500 is prohibited in sport by WADA (prohibited peptide and tissue-repair growth-factor categories) and classified as a prescription medicine in some countries. It has appeared as a doping agent in racehorses, prompting dedicated anti-doping detection methods [6]. No community-anecdote reports are compiled in this desk's source material for TB-500; the points above are from the cited literature. ## Where it fits in recovery research TB-500 occupies a particular position on this site: a compound whose *mechanism* — actin regulation driving cell migration — is well characterized at the protein level, but whose *evidence as the actual fragment sold* is the thinnest of the four [6][8]. Where [BPC-157](/bpc-157) leads with angiogenesis and [GHK-Cu](/ghk-cu) leads with collagen-matrix building and human topical data, TB-500's story is largely thymosin beta-4's story, borrowed. That makes it the clearest example of why this field rewards careful, specific reading. See how it compares on the [comparison page](/compare). ![TB-500 actin-binding heptapeptide fragment and cell-migration filaments](/images/tb-500.webp) --- Peer-reviewed research, summarized plainly — this is a reading digest, not a prescription pad.